Unknown

Dataset Information

0

IGF2BP1 is a targetable SRC/MAPK-dependent driver of invasive growth in ovarian cancer.


ABSTRACT: Epithelial-to-mesenchymal transition (EMT) is a hallmark of aggressive, mesenchymal-like high-grade serous ovarian carcinoma (HGSOC). The SRC kinase is a key driver of cancer-associated EMT promoting adherens junction (AJ) disassembly by phosphorylation-driven internalization and degradation of AJ proteins. Here, we show that the IGF2 mRNA-binding protein 1 (IGF2BP1) is up-regulated in mesenchymal-like HGSOC and promotes SRC activation by a previously unknown protein-ligand-induced, but RNA-independent mechanism. IGF2BP1-driven invasive growth of ovarian cancer cells essentially relies on the SRC-dependent disassembly of AJs. Concomitantly, IGF2BP1 enhances ERK2 expression in an RNA-binding dependent manner. Together this reveals a post-transcriptional mechanism of interconnected stimulation of SRC/ERK signalling in ovarian cancer cells. The IGF2BP1-SRC/ERK2 axis is targetable by the SRC-inhibitor saracatinib and MEK-inhibitor selumetinib. However, due to IGF2BP1-directed stimulation, only combinatorial treatment effectively overcomes the IGF2BP1-promoted invasive growth in 3D culture conditions as well as intraperitoneal mouse models. In conclusion, we reveal an unexpected role of IGF2BP1 in enhancing SRC/MAPK-driven invasive growth of ovarian cancer cells. This provides a rationale for the therapeutic benefit of combinatorial SRC/MEK inhibition in mesenchymal-like HGSOC.

SUBMITTER: Bley N 

PROVIDER: S-EPMC7951963 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

2020-08-24 | GSE147980 | GEO
| PRJNA622728 | ENA
| S-EPMC7941583 | biostudies-literature
| S-EPMC3492248 | biostudies-literature
| S-EPMC5007828 | biostudies-literature
| S-EPMC8695353 | biostudies-literature
| S-EPMC6326824 | biostudies-literature
| S-EPMC6557165 | biostudies-literature
2018-03-28 | GSE112371 | GEO
| S-EPMC7396249 | biostudies-literature